Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways.
air-liquid interface
interfacial delivery
lipid-protein interaction
pulmonary surfactant
respiratory drug delivery
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
10
2020
accepted:
21
12
2020
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
This work is focused on the potential use of pulmonary surfactant to deliver full-length recombinant human surfactant protein SP-D (rhSP-D) using the respiratory air-liquid interface as a shuttle. Surfactant protein D (SP-D) is a collectin protein present in the pulmonary surfactant (PS) system, involved in innate immune defense and surfactant homeostasis. It has been recently suggested as a potential therapeutic to alleviate inflammatory responses and lung diseases in preterm infants suffering from respiratory distress syndrome (RDS) or bronchopulmonary dysplasia (BPD). However, none of the current clinical surfactants used for surfactant replacement therapy (SRT) to treat RDS contain SP-D. The interaction of SP-D with surfactant components, the potential of PS as a respiratory drug delivery system and the possibility to produce recombinant versions of human SP-D, brings the possibility of delivering clinical surfactants supplemented with SP-D. Here, we used an
Identifiants
pubmed: 33542913
doi: 10.3389/fbioe.2020.613276
pmc: PMC7853302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
613276Informations de copyright
Copyright © 2021 García-Mouton, Hidalgo, Arroyo, Echaide, Cruz and Pérez-Gil.
Déclaration de conflit d'intérêts
RA was paid as part-time consultant by Airway Therapeutics Inc. JP-G has received research grants from Chiesi Farmaceutici spa and Airway Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biochim Biophys Acta Proteins Proteom. 2020 Aug;1868(8):140436
pubmed: 32325256
J Microsc. 2002 Feb;205(Pt 2):136-46
pubmed: 11879428
Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L468-76
pubmed: 10956621
Chest. 2007 Nov;132(5):1447-54
pubmed: 17925426
J Lipid Res. 2003 Mar;44(3):621-9
pubmed: 12562850
APMIS Suppl. 2000;100:1-59
pubmed: 11021254
Clin Exp Allergy. 2005 Apr;35(4):515-21
pubmed: 15836762
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
J Biol Chem. 1992 Oct 15;267(29):21244-9
pubmed: 1400434
Biochim Biophys Acta. 2008 Jul-Aug;1778(7-8):1676-95
pubmed: 18515069
Am J Respir Crit Care Med. 2010 May 15;181(10):1098-105
pubmed: 20133924
Pediatr Res. 2020 Aug;88(2):176-183
pubmed: 31926483
Nanomedicine (Lond). 2013 Oct;8(10):1625-38
pubmed: 23418856
J Intern Med. 2019 Feb;285(2):165-186
pubmed: 30357986
J Mol Biol. 2018 May 11;430(10):1495-1509
pubmed: 29626540
Biophys J. 1995 May;68(5):1937-43
pubmed: 7612835
Biochemistry. 1997 Jul 1;36(26):8173-9
pubmed: 9201966
J Control Release. 2020 Nov 24;329:205-222
pubmed: 33245954
Biochim Biophys Acta. 2012 May;1818(5):1225-34
pubmed: 22206628
Respir Res. 2000;1(2):93-108
pubmed: 11667972
Antimicrob Agents Chemother. 2015;59(6):3075-83
pubmed: 25753641
Biochemistry. 1992 Dec 8;31(48):12183-9
pubmed: 1457414
Physiology (Bethesda). 2010 Jun;25(3):132-41
pubmed: 20551227
Langmuir. 2017 Aug 15;33(32):7929-7939
pubmed: 28738158
J Biol Chem. 1998 Oct 23;273(43):28438-43
pubmed: 9774472
Am J Physiol. 1997 Aug;273(2 Pt 1):L468-77
pubmed: 9277461
Front Immunol. 2019 Mar 18;10:458
pubmed: 30936871
J Innate Immun. 2019;11(1):13-28
pubmed: 30293076
Chem Phys Lipids. 2015 Jan;185:153-75
pubmed: 25260665
Biochemistry. 1994 May 3;33(17):5121-7
pubmed: 8172887
J Clin Invest. 2001 Feb;107(4):467-75
pubmed: 11181646
Biochim Biophys Acta. 2012 Nov;1818(11):2756-66
pubmed: 22771553
Clin Exp Immunol. 2003 Nov;134(2):181-7
pubmed: 14616775
Int J Pharm. 2020 Jul 30;585:119387
pubmed: 32473376
Discov Med. 2018 Nov;26(144):207-218
pubmed: 30695680
J Appl Physiol (1985). 1998 Jul;85(1):333-52
pubmed: 9655794
Br J Pharmacol. 1996 Nov;119(6):1145-8
pubmed: 8937717
Immunobiology. 2007;212(3):201-11
pubmed: 17412287
J Biol Chem. 1994 Jun 24;269(25):17311-9
pubmed: 8006040
Biophys J. 2005 Sep;89(3):1769-79
pubmed: 15923228
J Innate Immun. 2013;5(3):197-208
pubmed: 23391661
Am J Physiol. 1999 Jan;276(1):L131-6
pubmed: 9887065
N Engl J Med. 2004 Aug 26;351(9):884-92
pubmed: 15329426
Curr Opin Pharmacol. 2006 Jun;6(3):277-83
pubmed: 16580255
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1342-7
pubmed: 16556693
Mol Immunol. 2019 Jan;105:260-269
pubmed: 30562646
Am J Respir Crit Care Med. 2009 Nov 15;180(10):989-94
pubmed: 19713451
Front Immunol. 2018 Sep 04;9:1998
pubmed: 30233589
Compr Physiol. 2015 Dec 15;6(1):363-422
pubmed: 26756637
Arch Dis Child. 2003 Nov;88(11):981-4
pubmed: 14612363
Eur J Pharm Biopharm. 2015 Sep;95(Pt A):117-27
pubmed: 25709061
Front Med (Lausanne). 2018 Feb 08;5:18
pubmed: 29473039
Am J Respir Cell Mol Biol. 2020 Sep;63(3):327-337
pubmed: 32348683
Am J Respir Cell Mol Biol. 1995 Apr;12(4):410-5
pubmed: 7695920